BLASUBCUTANEOUSSOLUTION
Approved
Aug 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOGROYA (somapacitan-beco) is a long-acting human growth hormone (hGH) analog administered via subcutaneous injection, developed by Novo Nordisk as a once-weekly alternative to daily GH therapies. It is indicated for growth hormone deficiency in adults and pediatric patients. The drug represents a significant advancement in GH replacement therapy by extending dosing intervals and improving patient convenience.
$0.163MPart D
PeakProduct is in peak commercial phase with modest Part D utilization, suggesting stable but limited Medicare penetration; team size likely stable or selective growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed
Started Oct 2023
200 enrolled
Growth Hormone Deficiency in Children
A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
Started Feb 2023
400 enrolled
Adult Growth Hormone Deficiency
Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®
Started Feb 2022
200 enrolled
Adult Growth Hormone Deficiency
Career Relevance
SOGROYA offers career opportunities in a niche but growing endocrinology market with established reimbursement and low clinical trial requirements. Working on this product emphasizes commercial acumen, payer management, and long-acting formulation expertise rather than discovery or early-stage development.
Worked on SOGROYA at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.